既往治疗HCC接受Y-90联合靶免治疗的预后因素探索
回顾性纳入30例既往治疗过的肝细胞癌患者,接受Y-90放射栓塞联合靶向及免疫治疗。中位随访9.7个月,客观缓解率37.5%,疾病控制率75.0%。既往手术史与更差的无进展生存相关,浸润性影像表现与治疗无反应相关,总胆红素、病灶数、GGT及肿瘤/正常肝摄取比与总生存有探索性关联。
要点
- 浸润性影像表现与Y-90联合靶免治疗后无反应相关,阅片时应重点描述肿瘤边缘形态。
- 既往手术史与更差的无进展生存相关,报告既往治疗史对本类患者预后评估有参考意义。
- 肿瘤/正常肝摄取比与总生存相关,核医学定量参数可纳入疗效随访观察。
核心结论
- 既往手术史与患者水平更差的无进展生存相关(HR 3.78,p=0.004)。
- 浸润性影像表现是唯一与治疗无反应相关的特征(p=0.042)。
- 总胆红素、病灶数、GGT和肿瘤/正常肝摄取比在单变量分析中与总生存有探索性关联。
研究设计与样本
- 回顾性探索性队列研究,纳入30例既往治疗过的肝细胞癌患者,其中11例有既往手术史,19例无。
- 所有患者接受Y-90放射栓塞联合靶向治疗及免疫治疗(Y-90 + TT + IT)。
- 中位随访9.7个月(95%CI,8.5-13.9),发生23例无进展生存事件和9例总生存事件。
- 24例患者完成患者水平疗效评估,评估条件为出现无进展生存事件或随访超过6个月且无进展。
- 因总生存事件数少(n=9),总生存分析为探索性;无进展生存采用单变量Cox回归及后退法多变量探索模型。
关键影像表现/征象
- 浸润性影像表现是唯一与治疗无反应相关的影像特征(p=0.042)。
- 客观缓解率37.5%(9/24),疾病控制率75.0%(18/24),提示影像随访中病灶变化可作为疗效观察指标。
- 病灶数在单变量分析中与总生存相关(p=0.022),阅片报告应明确可测量病灶数目。
诊断标准与关键数值
- 客观缓解率37.5%(9/24),疾病控制率75.0%(18/24),均为患者水平评估。
- 既往手术史与患者水平更差无进展生存相关(HR 3.78,p=0.004),多变量分析中仍显著(p=0.004)。
- 既往手术史与病灶水平更差无进展生存相关(HR 3.32,p=0.024),但敏感性分析限定每例一个指标病灶后不显著(p=0.128)。
- 总生存单变量关联:总胆红素p=0.019,病灶数p=0.022,GGT p=0.041,肿瘤/正常肝摄取比p=0.008。
临床应用与阅片要点
- 阅片时对肿瘤浸润性边缘形态应作明确描述,该征象与联合治疗后无反应相关。
- 对有既往手术切除史的肝细胞癌患者启动Y-90联合靶免治疗时,影像随访间期可能需要更密切。
- 影像报告中准确计数病灶数目可协助临床预后分层。
- 肿瘤/正常肝摄取比作为核医学定量指标,在随访中可辅助评估总生存相关风险。
局限性
- 回顾性单中心探索性研究,样本量仅30例,总生存事件仅9例,统计效力有限。
- 病灶水平既往手术史与无进展生存的关联在敏感性分析中未获确认,可能受患者内聚集效应影响。
- 总生存多变量分析未建立,相关关联仅为探索性假设,需更大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: To evaluate treatment response and identify factors associated with outcomes in previously treated hepatocellular carcinoma (HCC) patients receiving Y-90 radioembolization combined with targeted therapy and immunotherapy (Y-90 + TT + IT).
METHODS: This retrospective study included 30 previously treated HCC patients (11 with prior surgery, 19 without) who received Y-90 + TT + IT. At a median follow-up of 9.7 months (95% CI, 8.5-13.9), 23 PFS events and 9 overall survival (OS) events occurred. Patient‑level response was assessed in 24 patients (all with PFS events or > 6‑month follow‑up without progression). Univariable Cox regression was used for PFS and OS; owing to few OS events (n = 9), OS analyses were exploratory. For PFS, an exploratory multivariable model (backward stepwise) was also constructed.
RESULTS: Objective response rate was 37.5% (9/24) and disease control rate 75.0% (18/24); infiltrative imaging appearance was the only feature associated with non‑response (p = 0.042). Prior surgery was associated with worse PFS in both patient-level (HR 3.78, p = 0.004) and lesion-level (HR 3.32, p = 0.024) analyses; however, the lesion-level association was not confirmed in a sensitivity analysis restricted to one index lesion per patient (p = 0.128) and should be interpreted cautiously as it may reflect within‑patient clustering. Prior surgery remained significant in multivariable analysis (p = 0.004). In univariable analysis for OS, total bilirubin (p = 0.019), lesion number (p = 0.022), gamma-glutamyl transferase (GGT; p = 0.041), and tumor-to-normal liver uptake ratio (TNR; p = 0.008) were associated with OS.
CONCLUSIONS: In this exploratory cohort of previously treated HCC patients receiving Y-90 + TT + IT, prior surgery was associated with worse patient‑level PFS. Infiltrative imaging appearance was associated with non‑response. In univariable analysis, GGT, TNR, total bilirubin, and lesion number showed exploratory associations with OS. These findings generate hypotheses and require validation in larger prospective studies.
引用
- Chen, Wang, Li, et al. Prognostic factors and treatment response in previously treated hepatocellular carcinoma patients receiving Y-90 radioembolization combined with targeted-immunotherapy: an exploratory analysis. Abdom Radiol (NY). 2026. PMID: 42517902. doi:10.1007/s00261-026-05681-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。